UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 209

Sortiert nach

Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: A Gynecologic Oncology Group Study

Gynecologic oncology, 2010-01, Vol.116 (1), p.44-49

2010

Link zum Volltext

Verfügbarkeit prüfen

Mastering AutoCAD® 2018 and AutoCAD LT® 2018

1, 2017

Link zum Volltext

Verfügbarkeit prüfen

Mastering AutoCAD and AutoCAD LT

1st, 2017

Link zum Volltext

Verfügbarkeit prüfen

Mastering AutoCAD 2019 and AutoCAD LT 2019

George Omura, Brian C. Benton

1, 2018

Link zum Volltext

Verfügbarkeit prüfen

Progress in Gynecologic Cancer Research: The Gynecologic Oncology Group Experience

Seminars in oncology, 2008-10, Vol.35 (5), p.507-521

Omura, George A

2008

Link zum Volltext

Verfügbarkeit prüfen

Mastering AutoCAD 2017 and AutoCAD LT 2017

1, 2016

Link zum Volltext

Verfügbarkeit prüfen

Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia

The New England journal of medicine, 1994-10, Vol.331 (14), p.896-903

1994

Link zum Volltext

Verfügbarkeit prüfen

Phase III Trial of Paclitaxel at Two Dose Levels, the Higher Dose Accompanied by Filgrastim at Two Dose Levels in Platinum-Pretreated Epithelial Ovarian Cancer: An Intergroup Study

Journal of clinical oncology, 2003-08, Vol.21 (15), p.2843-2848

2003

Link zum Volltext

Verfügbarkeit prüfen

Modified Fibonacci search

Journal of clinical oncology, 2003-08, Vol.21 (16), p.3177-3177

Omura, George A

2003

Link zum Volltext

Verfügbarkeit prüfen

Re: early stage high-risk ovarian cancer

Gynecologic oncology, 2007-05, Vol.105 (2), p.555-6; author reply 556

Omura, George A

2007

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 dose-finding trials and fibonacci

Clinical cancer research, 2006-01, Vol.12 (1), p.321-321

Omura, George A

2006

Link zum Volltext

Verfügbarkeit prüfen

Re: Mucinous ovarian cancer

Gynecologic oncology, 2005-12, Vol.99 (3), p.789-789

Omura, George A.

2005

Link zum Volltext

Verfügbarkeit prüfen

The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: A gynecologic oncology group study

Gynecologic oncology, 1992-11, Vol.47 (2), p.159-166

1992

Link zum Volltext

Verfügbarkeit prüfen

Inhibitors of the enzyme purine nucleoside phosphorylase as potential therapy for psoriasis

Current pharmaceutical design, 2000-06, Vol.6 (9), p.943

2000

Link zum Volltext

Verfügbarkeit prüfen

Natural history and treatment of mycosis fungoides

Oncology (Williston Park, N.Y.), 2004-02, Vol.18 (2), p.144; author reply 144, 149-144; author reply 144

Omura, George A

2004

Link zum Volltext

Verfügbarkeit prüfen

A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma

Journal of the American Academy of Dermatology, 2001-06, Vol.44 (6), p.940-947

2001

Link zum Volltext

Verfügbarkeit prüfen

Flynn et al.: does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer?

Gynecologic oncology, 2003-08, Vol.90 (2), p.498-498

Omura, George A.

2003

Link zum Volltext

Verfügbarkeit prüfen

Darier, Pautrier, and the “microabscesses” of mycosis fungoides

Journal of the American Academy of Dermatology, 2002-02, Vol.46 (2), p.320-321

Omura, George A.

2002

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and Pharmacodynamics of Peldesine (BCX-34), a Purine Nucleoside Phosphorylase Inhibitor, following Single and Multiple Oral Doses in Healthy Volunteers

Journal of clinical pharmacology, 2000-04, Vol.40 (4), p.410-420

2000

Link zum Volltext

Verfügbarkeit prüfen

Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma. Cancer and Leukemia Group B studies 8852 and 8854

Cancer, 2001-07, Vol.92 (2), p.207-217

2001

Link zum Volltext

Verfügbarkeit prüfen

Age as a prognostic factor in ovarian carcinoma: The gynecologic oncology group experience

Cancer, 1993-01, Vol.71 (S2), p.606-614

1993

Link zum Volltext

Verfügbarkeit prüfen

Using the Expected Survival to Explain Differences Between the Results of Randomized Trials: A Case in Advanced Ovarian Cancer

Journal of clinical oncology, 2003-05, Vol.21 (9), p.1682-1687

2003

Link zum Volltext

Verfügbarkeit prüfen

Progress in Gynecologic Cancer Research : The Gynecologic Oncology Group Experience: Contributions of the Cooperative Groups

Seminars in oncology, 2008, Vol.35 (5), p.507-521

OMURA, George A

2008

Link zum Volltext

Verfügbarkeit prüfen

George A. Omura, MD, on Giving, and Not Giving, Chemotherapy

Oncology times, 2004-08, Vol.26 (15), p.7-7

Omura, George A

2004

Link zum Volltext

Verfügbarkeit prüfen

Letter to the Editor

Gynecologic oncology, 2007-05, Vol.105 (2), p.555-556

Omura, George A.

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 209

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(117)
Mit Volltextzugriff
(193)

Publikationsform

Artikel
(123)
Buchkapitel
(80)
Bücher
(6)

Sprache

Englisch
(208)
Japanisch
(15)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(86)
Humans
(81)
Life Sciences & Biomedicine
(80)
Female
(53)
Oncology
(45)
General Engineering & Project Administration
(39)
General References
(39)
Middle Aged
(38)
Biological And Medical Sciences
(36)
Medical Sciences
(34)
Adult
(32)
Aged
(29)
Male
(29)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(27)
Pharmacology. Drug Treatments
(26)
Antineoplastic Agents
(22)
Autocad
(21)
Chemotherapy
(21)
Cyclophosphamide - Administration & Dosage
(15)
Doxorubicin - Administration & Dosage
(15)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: A Gynecologic Oncology Group Study

Mastering AutoCAD® 2018 and AutoCAD LT® 2018

Mastering AutoCAD and AutoCAD LT

Mastering AutoCAD 2019 and AutoCAD LT 2019

Progress in Gynecologic Cancer Research: The Gynecologic Oncology Group Experience

Mastering AutoCAD 2017 and AutoCAD LT 2017

Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia

Phase III Trial of Paclitaxel at Two Dose Levels, the Higher Dose Accompanied by Filgrastim at Two Dose Levels in Platinum-Pretreated Epithelial Ovarian Cancer: An Intergroup Study

Modified Fibonacci search

Re: early stage high-risk ovarian cancer

Phase 1 dose-finding trials and fibonacci

Re: Mucinous ovarian cancer

The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: A gynecologic oncology group study

Inhibitors of the enzyme purine nucleoside phosphorylase as potential therapy for psoriasis

Natural history and treatment of mycosis fungoides

A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma

Flynn et al.: does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer?

Darier, Pautrier, and the “microabscesses” of mycosis fungoides

Pharmacokinetics and Pharmacodynamics of Peldesine (BCX-34), a Purine Nucleoside Phosphorylase Inhibitor, following Single and Multiple Oral Doses in Healthy Volunteers

Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma. Cancer and Leukemia Group B studies 8852 and 8854

Age as a prognostic factor in ovarian carcinoma: The gynecologic oncology group experience

Using the Expected Survival to Explain Differences Between the Results of Randomized Trials: A Case in Advanced Ovarian Cancer

Progress in Gynecologic Cancer Research : The Gynecologic Oncology Group Experience: Contributions of the Cooperative Groups

George A. Omura, MD, on Giving, and Not Giving, Chemotherapy

Letter to the Editor

Suchergebnisse filtern